July 24, 2020
Investors in biopharmaceutical company Aeterna Zentaris Inc. asked a New Jersey federal judge Thursday to approve a $6.5 million deal to end class action allegations that the company lied about the success of a potential new hormone deficiency drug, causing its stock price to plummet.